Trials / Terminated
TerminatedNCT05382715
A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative Colitis
Ulcerative Colitis in Subjects of Clinical Routine: A Four Year, Multicenter, Prospective, Non-Interventional Study to Evaluate Utilization, Effectiveness, and Quality of Life With Ozanimod
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 175 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to monitor the use, effectiveness and treatment persistence with Ozanimod (Zeposia®) as well as quality of life in participants undergoing treatment for moderate-to-severe ulcerative colitis (UC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ozanimod | Specified Dose on Specified Days |
Timeline
- Start date
- 2022-05-30
- Primary completion
- 2025-05-31
- Completion
- 2025-05-31
- First posted
- 2022-05-19
- Last updated
- 2025-07-02
Locations
1 site across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05382715. Inclusion in this directory is not an endorsement.